Gastro-

United States Gastro-Intestinal Stromal Tumors Market and Competitive Landscape Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 16, 2021
Pharmaceutical, Health, Oncology, Biological nomenclature, Gastro-, Prefixes

The "US Gastro-Intestinal Stromal Tumors Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Gastro-Intestinal Stromal Tumors Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • US Gastro-Intestinal Stromal Tumors Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Gastro-Intestinal Stromal Tumors pipeline products, Gastro-Intestinal Stromal Tumors epidemiology, Gastro-Intestinal Stromal Tumors market valuations and forecast, Gastro-Intestinal Stromal Tumors drugs sales and competitive landscape in the US.
  • Gastro-Intestinal Stromal Tumors pipeline: Find out the products in clinical trials for the treatment of Gastro-Intestinal Stromal Tumors by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Gastro-Intestinal Stromal Tumors drugs: Identify key products marketed and prescribed for Gastro-Intestinal Stromal Tumors in the US, including trade name, molecule name, and company
    Gastro-Intestinal Stromal Tumors drugs sales: Find out the sales revenues of Gastro-Intestinal Stromal Tumors drugs in the US
    Gastro-Intestinal Stromal Tumors market valuations: Find out the market size for Gastro-Intestinal Stromal Tumors drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Gastro-Intestinal Stromal Tumors drugs market share: Find out the market shares for key Gastro-Intestinal Stromal Tumors drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Gastro-Intestinal Stromal Tumors products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005773/en/

SMART Medical Systems receives Additional FDA Clearance for its G-EYE® Colonoscope, and Commences Clinical Work in the USA

Retrieved on: 
Tuesday, February 16, 2021
Clinical medicine, Medicine, Medical specialties, Diagnostic gastroenterology, Digestive system, Cancer screening, Large intestine, Colonoscopy, Gastrointestinal tract, Endoscopy, Gastro-

The G-EYEColonoscope is a 510(k) cleared colonoscope, remanufactured by SMART to include a proprietary balloon at its distal bending section.

Key Points: 
  • The G-EYEColonoscope is a 510(k) cleared colonoscope, remanufactured by SMART to include a proprietary balloon at its distal bending section.
  • Withdrawal of the G-EYEColonoscope with the balloon moderately inflated during colonoscopy, assists in controlling the colonoscope's field of view and positioning.
  • SMART Medical Systems is a pioneer in the development and manufacture of innovative medical devices in the field of gastro-intestinal (GI) endoscopy.
  • SMART is headquartered in Israel, and operates in the United States through its wholly-owned subsidiary, SMART GI Inc. For more information, please visit: www.smartmedsys.com/us/ .

SMART Medical Systems receives Additional FDA Clearance for its G-EYE® Colonoscope, and Commences Clinical Work in the USA

Retrieved on: 
Tuesday, February 16, 2021
Clinical medicine, Medicine, Medical specialties, Diagnostic gastroenterology, Digestive system, Cancer screening, Large intestine, Colonoscopy, Gastrointestinal tract, Endoscopy, Gastro-

The G-EYEColonoscope is a 510(k) cleared colonoscope, remanufactured by SMART to include a proprietary balloon at its distal bending section.

Key Points: 
  • The G-EYEColonoscope is a 510(k) cleared colonoscope, remanufactured by SMART to include a proprietary balloon at its distal bending section.
  • Withdrawal of the G-EYEColonoscope with the balloon moderately inflated during colonoscopy, assists in controlling the colonoscope's field of view and positioning.
  • SMART Medical Systems is a pioneer in the development and manufacture of innovative medical devices in the field of gastro-intestinal (GI) endoscopy.
  • SMART is headquartered in Israel, and operates in the United States through its wholly-owned subsidiary, SMART GI Inc. For more information, please visit: www.smartmedsys.com/us/ .

Global Gastric and Gastroesophageal Junction Adenocarcinoma Drug Market Report 2020: Disparity in Adoption of Nationwide Screening Programs Hinders Early Stage Disease Diagnosis in the US and 5EU

Retrieved on: 
Tuesday, November 24, 2020
Infectious causes of cancer, Cancer, Clinical medicine, Neoplasms, Gastrointestinal cancer, Neuroendocrine tumor, Neuroendocrinology, Pancreatic cancer, Adenocarcinoma, HER2/neu, Gastro-

DUBLIN, Nov. 24, 2020 /PRNewswire/ -- The "Gastric and Gastroesophageal Junction Adenocarcinoma - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 24, 2020 /PRNewswire/ -- The "Gastric and Gastroesophageal Junction Adenocarcinoma - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.
  • Approximately 90-95% of G/GEJACs are adenocarcinomas, while the rest represent rarer gastric malignancies, such as gastrointestinal stromal tumors, lymphomas, and neuroendocrine tumors.
  • Historically, treatment of G/GEJAC has been mostly reliant on chemotherapy, with this remaining the mainstay for HER2-negative patients.
  • The new competitive landscape will be driven by novel HER-2 targeting agents, novel biomarker-driven therapies and the label expansions of immunotherapies.

Global Gastric and Gastroesophageal Junction Adenocarcinoma Drug Forecast and Market Analysis 2019-2029 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 17, 2020
Pharmaceutical, Health, Oncology, Infectious causes of cancer, Anatomy, Medical specialties, Cancer, Gastrointestinal cancer, Abdomen, Adenocarcinoma, Gastro-, Neuroendocrine tumor, Stomach, Gastric lymphoma, Andecaliximab

The "Gastric and Gastroesophageal Junction Adenocarcinoma - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gastric and Gastroesophageal Junction Adenocarcinoma - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.
  • Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) is the fifth most common form of cancer and the fourth leading cause of cancer-related death worldwide, yet little is known about its exact etiology despite much ongoing research.
  • Approximately 90-95% of G/GEJACs are adenocarcinomas, while the rest represent rarer gastric malignancies, such as gastrointestinal stromal tumors, lymphomas, and neuroendocrine tumors.
  • Analysis of the current and future market competition in the global G/GEJAC therapeutics market.

Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting

Retrieved on: 
Monday, November 2, 2020
Medical specialties, Organ systems, Clinical medicine, Immune system disorders, Eosinophilic esophagitis, Eosinophilic gastroenteritis, Gastritis, Esophagitis, Duodenitis, Gastrointestinal tract, Gastrointestinal disease, Gastro-

In addition, the poster abstract (S1330) appears in the supplement to the October 2020 issue of the American Journal of Gastroenterology.

Key Points: 
  • In addition, the poster abstract (S1330) appears in the supplement to the October 2020 issue of the American Journal of Gastroenterology.
  • Eosinophilic gastritis, eosinophilic duodenitis (previously referred to as eosinophilic gastroenteritis), and eosinophilic esophagitis are chronic, often severe, inflammatory diseases characterized by the presence of high levels of eosinophils in the stomach, duodenum, or esophagus, respectively.
  • The current estimated prevalence of eosinophilic gastritis and eosinophilic duodenitis inthe United Statesis approximately 50,000 people.
  • The Company believes that these diseases may be significantly under-diagnosed, or misdiagnosed, as other gastrointestinal diseases.

Global Gastro-Esophageal Reflux Disease Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 19, 2020
Health, Pharmaceutical, RTT, Medical specialties, Gastroenterology, Esophageal cancer, Gastrointestinal cancer, Gastroesophageal reflux disease, Gastro-, Organ systems

The "Global Gastro-Esophageal Reflux Disease Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Gastro-Esophageal Reflux Disease Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • Global Gastro-Esophageal Reflux Disease Market and Competitive Landscape - 2020, provides comprehensive insights into the Gastro-Esophageal Reflux Disease pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Gastro-Esophageal Reflux Disease market size and drug sales.
  • Gastro-Esophageal Reflux Disease pipeline: Find out drugs in clinical trials for the treatment of Gastro-Esophageal Reflux Disease by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Gastro-Esophageal Reflux Disease drugs: Identify key drugs marketed and prescribed for Gastro-Esophageal Reflux Disease in the US, including trade name, molecule name, and company
    Gastro-Esophageal Reflux Disease drugs sales: Find out the sales value for Gastro-Esophageal Reflux Disease drugs by countries
    Gastro-Esophageal Reflux Disease market valuations: Find out the market size for Gastro-Esophageal Reflux Disease drugs in 2019 by countries.

Motus GI Hosting Key Opinion Leader Call on Improving Endoscopy Outcomes with the Pure-Vu® System

Retrieved on: 
Tuesday, October 13, 2020
Clinical medicine, Medicine, Diagnostic gastroenterology, Medical specialties, Endoscopy, RTT, Colonoscopy, Motus, Colorectal cancer, Gastro-, Large intestine

Motus GI's management team will also provide an update on the Pure-Vu System, a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure.

Key Points: 
  • Motus GI's management team will also provide an update on the Pure-Vu System, a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure.
  • Within the last year, the Company initiated its commercial launch of the Pure-Vu System in the U.S. with an initial focus on inpatient colonoscopy.
  • Gross research interests lie in the area of gastrointestinal malignancies as well as quality and innovation in endoscopy.
  • Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.

Global Gastro-Intestinal Stromal Tumor Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 12, 2020
Health, Oncology, Biological nomenclature, Gastro-, Prefixes, Stromal tumor

The "Global Gastro-Intestinal Stromal Tumor Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Gastro-Intestinal Stromal Tumor Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • Global Gastro-Intestinal Stromal Tumor Market and Competitive Landscape - 2020, provides comprehensive insights into the Gastro-Intestinal Stromal Tumor pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Gastro-Intestinal Stromal Tumor market size and drug sales.
  • Gastro-Intestinal Stromal Tumor pipeline: Find out drugs in clinical trials for the treatment of Gastro-Intestinal Stromal Tumor by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Gastro-Intestinal Stromal Tumor drugs: Identify key drugs marketed and prescribed for Gastro-Intestinal Stromal Tumor in the US, including trade name, molecule name, and company
    Gastro-Intestinal Stromal Tumor drugs sales: Find out the sales value for Gastro-Intestinal Stromal Tumor drugs by countries
    Gastro-Intestinal Stromal Tumor market valuations: Find out the market size for Gastro-Intestinal Stromal Tumor drugs in 2019 by countries.

Worldwide Gastro-Intestinal Stromal Tumors Industry (2020 to 2024) - In-depth Knowledge of Competition and Markets - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 1, 2020
Pharmaceutical, Health, Oncology, Biological nomenclature, Gastro-, Prefixes

The "Global Gastro-Intestinal Stromal Tumors Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Gastro-Intestinal Stromal Tumors Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights into the Gastro-Intestinal Stromal Tumors pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Gastro-Intestinal Stromal Tumors market size and drug sales.
  • Gastro-Intestinal Stromal Tumors pipeline: Find out drugs in clinical trials for the treatment of Gastro-Intestinal Stromal Tumors by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Gastro-Intestinal Stromal Tumors drugs: Identify key drugs marketed and prescribed for Gastro-Intestinal Stromal Tumors in the US, including trade name, molecule name, and company
    Gastro-Intestinal Stromal Tumors drugs sales: Find out the sales value for Gastro-Intestinal Stromal Tumors drugs by countries
    Gastro-Intestinal Stromal Tumors market valuations: Find out the market size for Gastro-Intestinal Stromal Tumors drugs in 2019 by countries.